NuvoAir

Executive Summary

NuvoAir is a Stockholm-based digital health company founded in 2017, dedicated to transforming management of chronic heart and lung conditions through a virtual-first, personalized care platform. The company integrates FDA-cleared remote monitoring devices, such as spirometers and pulse oximeters, with advanced data analytics and 24/7 clinical support. This enables real-time tracking of patient metrics, early detection of exacerbations, and tailored care plans for conditions like COPD, asthma, and heart failure. By empowering patients and providers with actionable insights, NuvoAir aims to improve clinical outcomes while reducing healthcare costs—a critical value proposition as health systems seek scalable remote care solutions. NuvoAir has positioned itself at the intersection of respiratory care and digital therapeutics, a segment experiencing rapid growth due to aging populations and rising chronic disease prevalence. The company's platform is validated by its FDA-cleared devices and has potential for expansion into new geographies and disease areas. Key upcoming catalysts include regulatory milestones for next-generation devices, strategic partnerships with healthcare organizations, and potential funding rounds to fuel commercial growth. With strong tailwinds from the shift toward value-based care and remote patient monitoring, NuvoAir is well-placed to capture market share in the digital health ecosystem.

Upcoming Catalysts (preview)

• Q3 2026FDA clearance for next-generation spirometer with enhanced AI analytics70% success
• Q2 2026Strategic partnership with a major European hospital network for pilot deployment60% success
• Q4 2026Series B funding round led by prominent health-tech investors80% success